Monopar Therapeutics (MNPR) Non-Current Assets (2016 - 2026)
Monopar Therapeutics (MNPR) posted Non-Current Assets of $254921.0 for Q4 2025, up 138.99% sequentially from $106666.0 in Q3 2025.
Monopar Therapeutics (MNPR) Non-Current Assets (2016 - 2026) Analysis & Trends
Monopar Therapeutics has reported Non-Current Assets for 9 years, with the latest figure at $254921.0 in Q4 2025.
- Quarterly Non-Current Assets changed N/A year-over-year to $254921.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $488859.0 (changed N/A YoY) and the FY2025 annual result came in at $254921.0, changed N/A from the prior year.
- Non-Current Assets climbed to $254921.0 in Q4 2025 per MNPR's latest filing, from $106666.0 in the prior quarter.
- Over five years, Non-Current Assets peaked at $254921.0 in Q4 2025 and troughed at $9102.0 in Q1 2025.
- A 4-year average of $72803.1 and a median of $68858.0 in 2021 frame the typical range for Non-Current Assets.
- The sharpest annual moves came in 2022 and 2023: Non-Current Assets increased 22.52% in 2022, then slumped 79.35% in 2023.
- Over 4 years, Non-Current Assets stood at $68858.0 in 2021, then dropped by 11.08% to $61228.0 in 2022, then plunged by 79.35% to $12646.0 in 2023, then jumped by 1915.82% to $254921.0 in 2025.
- According to Business Quant data, Non-Current Assets over the past three periods registered $254921.0, $106666.0, and $118170.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 14.88 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 23.28 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.96 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 294.93 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.96 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 3.76 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 18.06 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 938.60 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 468.65 Mn |
| 10 | Monopar Therapeutics | 965.64 Mn | 912.88 Mn | - | 215,120.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 215,120.00 |
| Dec 31, 2025 | 254,921.00 |
| Sep 30, 2025 | 106,666.00 |
| Jun 30, 2025 | 118,170.00 |
| Mar 31, 2025 | 9,102.00 |
| Dec 31, 2023 | 12,646.00 |
| Sep 30, 2023 | 25,088.00 |
| Jun 30, 2023 | 37,330.00 |
| Mar 31, 2023 | 49,376.00 |
| Dec 31, 2022 | 61,228.00 |
| Sep 30, 2022 | 72,889.00 |
| Jun 30, 2022 | 84,363.00 |
| Mar 31, 2022 | 53,694.00 |
| Sep 30, 2021 | 68,858.00 |
| Jun 30, 2021 | 68,858.00 |
| Mar 31, 2021 | 68,858.00 |
| Dec 31, 2020 | 68,858.00 |
| Sep 30, 2020 | 68,858.00 |
| Jun 30, 2020 | 73,050.00 |
| Mar 31, 2020 | 122,381.00 |